Synthesis and Comparative Study of Anti-Adenoviral Activity of 6-Azacytidine and Its Analogues.

This paper presents the results of synthesis and study of cytotoxicity and the anti-adenoviral activity of new N4-derivatives of 6-azacytidine and its α-L-glycopyranosyl analogues obtained by the simplified one-pot version of the silyl condensation method. The resulting acylated 4-methylmercapto-1,2,4-triazin-3(2Н)-one glycosides then underwent the amination and/or ammonolysis to provide 6-azacytidine glycoside analogues (2-6, 12, 15, 17) and compounds with modifications at both base and sugar fragments (11, 15). The evaluation of cytotoxicity and antiviral activity of new compounds against AdV5 showed high selectivity indexes for N4-methyl-6-azacytidine (2) and N,O-tetraacetyl-6-azacytidine (8).

Inhibitors of Epstein-Barr virus reproduction--ribonucleosides of 3-substituted 1,2,4-triazino[5,6-b] [1,4] benzothiasines.

Studying of antiviral effect of condensed triazine derivatives--3-oxo- triazinobenzothiazine (the preparation No 1), its ribonucleoside (the preparation No 3) and ribonucleoside of its 3-thio-analogue (the preparation No 2) on reproduction of Epstein-Barr virus (EBV) in lymphoblastoid Raji cells is reported in present work. The cytotoxic action of these preparations on test cells was determined and CC50 index was 125 microg/ml for the preparation No 1, for preparation No 2 - 625 microg/ml, and for preparation No 3 - 750 microg/ml. Antiviral activity of the preparations was tested by inhibition level of accumulation of viral DNA in the cell culture, and effective concentration (EC50 index) was determined for each preparation.

[Application of clexane in urosepsis: necessity or the issue of fashion].

Results of comparative studying of influence of low-molecular weight heparin clexane (enoxaparine sodium) and nonfractionized heparin on coagulational properties of blood in patients with uncomplicated urosepsis are presented. It was established that application of clexane promotes an effective prophylaxis of thromboembolic complications without rising of the hemorrhage occurrence risk.